These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38769817)

  • 21. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
    Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
    Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.
    Bajwa R; Cheema A; Khan T; Amirpour A; Paul A; Chaughtai S; Patel S; Patel T; Bramson J; Gupta V; Levitt M; Asif A; Hossain MA
    J Clin Med Res; 2019 Apr; 11(4):225-236. PubMed ID: 30937112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
    Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
    Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
    Kejamurthy P; Devi KTR
    Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
    Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
    South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.
    Okura N; Asano M; Uchino J; Morimoto Y; Iwasaku M; Kaneko Y; Yamada T; Fukui M; Takayama K
    J Clin Med; 2020 Jun; 9(7):. PubMed ID: 32610470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
    Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
    Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
    Kocheise L; Piseddu I; Vonderlin J; Tjwa ET; Buescher G; Meunier L; Goeggelmann P; Fianchi F; Dumortier J; Riveiro Barciela M; Gevers TJG; Terziroli Beretta-Piccoli B; Londoño MC; Frankova S; Roesner T; Joerg V; Schmidt C; Glaser F; Sutter JP; Fründt TW; Lohse AW; Huber S; von Felden J; Sebode M; Schulze K
    Front Immunol; 2023; 14():1326078. PubMed ID: 38268921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
    Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
    Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
    González-Rodríguez E; Rodríguez-Abreu D;
    Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis.
    Karna R; S Deliwala S; Ramgopal B; Asawa P; Mishra R; P Mohan B; Jayakrishnan T; Grover D; Kalra T; Bhalla J; Saraswati U; K Gangwani M; Dhawan M; G Adler D
    Immunotherapy; 2023 Jul; 15(10):773-786. PubMed ID: 37190949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
    Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
    Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects.
    Dalvin LA; Shields CL; Orloff M; Sato T; Shields JA
    Retina; 2018 Jun; 38(6):1063-1078. PubMed ID: 29689030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.